# LUVOX® (fluvoxamine maleate) Tablets

Brief Summary of prescribing information (based on 8E1252 Rev 3/97) See package insert for full prescribing information.

# INDICATIONS AND USAGE

LIVOX Tablets are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD), as defined in the DSM-IIIR. Obsessive Compulsive Disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable.

adine, asternizole, or cisapride with LUVOX Tablets is contraindicated (see WARNINGS and PRECAUTIONS) Co-administration of terfena

LUVOX Tablets are contraindicated in patients with a history of hypersensitivity to fluvoxamine maleate

UNOX lables or containdanced in potents with a history of hypesensitivity to fluvocamine molecule.

WARNINGS

In patients receiving another serotonis respitake inhibitor drug in combination with monoamine oxidose inhibitors (MAOIs), there have been reports of serious, sometimes ford, reactions. Therefore, it is recommended that LUVOX® Tablets not be used in combination with a MAOI, or within 14 days of discontinuing treatment with a MAOI. In addition, after stopping LUVOX® Tablets, at least 2 weeks should be ellowed before starting a MAOI.

Terfesedine, astemizole and cisquride are all metabolized by the cytochrome P450IIIA4 isoenzyne. Increased plasmic concentrations of Inferioratione, astemizole and cisquride cause on Tyrolongation and have been associated with torsales de points-type ventricoler tackycardia, sometimes fartal. Although it has not been definitively domonstrated that fluvoxamine is a potent IIIAA inhibitor, it is likely to be. Consequently, it is recommended that fluvoxamine not be used in combination with either terhonodine, estemizole, or disagrade.

Other Patentially Important Drug Interactions

(Also see PRECAUTIONS - Dung Interactions) Bezzadiazopines: Bezzadiazopines metabolized by phapatic axidation (e.g., adprazolem, midazolem, thiracolem, etc.) should be used with customin because the clearance of these drugs is likely to be reduced by fluvoxamine. Alprazolem—When fluvoxamine metabolized by glucuondiation (e.g., lorazopem, conzepum, termazopem) is unlikely to be effected by fluvoxamine. Alprazolem—When fluvoxamine metabolized by glucuondiation (e.g., lorazopem, moxepum, termazopem) is unlikely to be effected by fluvoxamine. Alprazolem—When fluvoxamine metabolized by glucuondiation (e.g., lorazopem—When fluvoxamine reduced physical and patrolam (e.g. disparacellam physical physicales and physical physical physical physical physical physical phys

General Activation of Mensia / Hypomania: During premarketing studies involving primarily depressed patients, hypomania or mania occurred in approximately 3% of patients treated with fluroxomine. Activation of mania /hypomania has also been reported in a small proportion of patients with major offective disorder who were treated with other marketed antidepressants. As with all antidepressants, LIVOX Tablets should be used countously in patients with a lostony of mania. Selzurees: During premarketing studies, seizures were reported in 2.2% of fluroxomania herated patients. LIVOX Tablets should be used controlled; the passibility of a suicide attempt is inherent in patients with a depressive symptoms, whether these occur in primary depression or in association with enother primary disorders such as OLO. Glose supervision of high risk patients should accompany rised days thereof. Prescriptions for LIVOX Tablets should be written for the smallest quantity of tablets consistent with page displayment in order to reduce the risk of overdase. Use in Patients with Concomitant Illness: Closely or portions with a consistent with page displayment in order to reduce the risk of overdase. Use in Patients with Concomitant Illness: Closely to potents with diseases or conditions that could direct hemodynamic responses or metabolism. LIVOX Tablets have not been evaluated or used to proprient swith diseases. Patients with the adaptive or such a support of the proprients with the effective or proprients with the proprient with order or COV who participated in premarketing studies from a full inflamment or proprients with the opportunity of the proprients with the effective disputation. The proprients with the proprient State for the proprient studies or confidence or confidence was decreased by approximately 30%. LIVOX Tablets should be slowly tirreted in patients with itself proprients. Interference with Cognitive or Motor Patients.

Information for Patients
Physicians are advised to discuss the following issues with patients for whom they prescribe LUVOX Tablets: Interference with Cognitive or Motor
Performance: Since any psychocotive drug may impair judgement, thinking, or motor skills, patients should be continued about operating hazardous
machineny; including outernabiles, until they are certain that LUVOX Tablets therapy does not adversely affect their ability to engage in such activities.
Pergenency: Potents should be advised to notify their physicians if they are beaust feeding on infant. (See PECAUTIONS - Nursing: Patients receiving LUVOX Tablets should be advised to notify their physicians if they are beaust feeding on infant. (See PECAUTIONS - Nursing
Mothers). Concomitant Medication: Patients should be advised to notify their physicians if they are based politically importance intercons with LUVOX Tablets. Acknobet. As with other psychothopic medications, potents should be advised to avoid alcohol while taking LUVOX Tablets. All patients: Patients should be advised to notify their physicians if they develop a rosh, hives, or a related allergic phenomenon during therapy with LUVOX Tablets.

Laboratory Tests:

There are no specific laboratory tests recommended.

Laboratory Tests
There are no specific laboratory tests recommended.

Drug lateractices
There have been rare postmarking reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective seriotoria recyptate inhibitor (SSR) and sumotriplan. If concomitant treatment with sumotriplan and an SSRI (e.g., fluoretine, fluorosamine, provedine, serticiline) is clinically worranted, appropriate observation of the patient is odivised. Patiential interactions with drugs short inhibitor or are Metabolized by Cytechrome P450 (sexymes: Based on a finding of substantial interactions of fluorosamine with certain drugs and limited in vivo data for substantial interactions of fluorosamine with certain drugs such as warfain, theophyline and prosponalol. A clinically significant flavorosamine interaction is possible with drugs baving a narrow therapeutic roto such as seferacidine, estemazed exognize plants of phyline, perioparative, estemazed exognized, in the metabolism and has a narrow therapeutic window, plasma levels and/or pharmocolynomic effects of the latter drug should be monitored closely, at least until steady state conditions are reacted. Please see complete prescribing information for recommendations regarding CKS drugs such as monarisms with such such as a least plant plants of the properties of the prop

Pregnancy
Terratogenic Effects - Pregnancy Category C: In terratology studies in rats and rabbits, daily and doses of fluoroamine maleate of up to 80 and
40 mg/kg, respectively (approximately 2 lines the maximum human daily dose on a mg/m² basis) caused no feral malformations. However, in other
reproduction studies in which pregnant rats were dosed through weaning there was (1) an increase in purp mortality of birth (seen at 80 mg/kg and south of 10 mg/kg and south (seen at 80 mg/kg and south 65 mg/kg) and (2) doseroses in postantial up weights (seen at 160 but not at 20 mg/kg) and south (seen at 80 mg/kg and south 65 mg/kg) and south (seen at 80 mg/kg and south 65 mg/kg) and south 65 mg/kg) and south 65 mg/kg). (100 seen 51 5, 20, 80, and 160 mg/kg are approximately 0.1, 0.5, 2, and 4 times the maximum human daily dose on a mg/m² basis.)
While the mestic of a crossfortering shut implied that a fleet stars one of these results kiety occurred secondarily to maternal tractive, and of the controlled studies in pregnant women. Howaranine maleate should be used during pregnancy only if the potential benefit justifies the potential task to the fetus.

Labor and Deflevery
The effect of throwarmine on labor and delivery in humans is unknown.

Newsiew Morthers:

# Nursing Mothers

As for many other drugs, fluvexamine is secreted in human breast milk. The decision of whether to discontinue nuising or to discontinue the drug should take into occount the potential for serious odverse effects from exposure to fluvoxamine in the nuising infant as well as the potential benefits of LUYOX\* (fluvoxamine maleate) Tablets therapy to the mother.

# Pediatric Use

Predictive Use
The efficiacy of fluvoxomine molecte for the treatment of Obsessive Compulsive Disorder was demonstrated in a 10-week multirenter placebo controlled study with 120 outpatients ages 8-17. The adverse event profile observed in that study was generally similar to that observed in adult studies with fluvoxomine (see ADVERSE REACTIONS).

becaused appetite and weight loss have been observed in association with the use of fluvoxamine as well as other SSRIs. Consequently, regular monitoring of weight and growth is recommended if treatment of a child with an SSRI is to be continued long term.

# Geriatric Use

Centaria: Use
Approximately 230 potients participating in controlled premarketing studies with LUVOX Tobbets were 65 years of age or over. No overall differences in safety were observed between these potients and younger potients. Other reported clinical experience has not identified differences in response between the elderly and younger potients. However, the cleanance of thronzamine is decreased by about 50% in elderly compared to younger potients is between the elderly and proper potients. However, the cleanance of thronzamine is decreased by about 50% in elderly compared to younger potients see Phormacokinetrus under PARPARCHICOGT), and greater sensitivity of some older individuods also cannot be ruled out. Consequently, LUVOX tablests should be slowly introded during militation

Associated with Discontinuation of Treatment
Of the 1087 OCD and depressed patients neated with fluvoxomine malecte in controlled clinical trials conducted in North America, 22% discontinued

Adverse events in OCD Pediatric Population
In pediatric potients (N=57) treated with LUVOX\* Tablets, the overall profile of adverse events is similar to that seen in adult studies. Other reactions which in pediating patients (vi=37) release with COVA. Tolleris, the event profits of request events 5 shallow to land seem in obsolutions boules. Since events have been reported in two or more of the pediatric patients, and were more frequent than in the placebo group (N=63) were: obnoral labeling, cough increase, dysmenarchea, exchymosis, emotional labeling, pistoxis, hypekinesia, unlection, manic reaction, assis, sinustris, and weight devierse. Events for which the incidence in fluoroximine malerate was equal to or less than the incidence in placebo (N=63) and involved two or more of the pediatric

Events for which the incidence in throxomniae maleate was equal to or less than the incidence in placebo (M-6-3) and involved two or more of the pediatric subdy potents were coloration point, almost modern and involved the coloration point, almost more described in the coloration point. Incidence in Controlled Clinical Trials - Commonly Observed Adverse Events in Controlled Clinical Trials: LIVOX Toblets have been studied in controlled this of OCD (m-320) and depression (n-1350). In general, obverse event rates were similar in the two data sets. The most commonly observed odverse events associated with the use of LIVOX Toblets and likely to be dug-related (incidence of 5% or geneter and of least have that for placebo) derived overse events associated with me use of LUVA. Balest and likely to be drug-related incidence of 5% or geneter and of least twice that for procedo deneter from Table 2 were summelance, insortain, enervousness, herman, nauses, objection, constrained, promitting, abnormal ejeculation, ostationed seventing in a pool of two studies involving only patients with OCD, the following additional events were identified using the above rule: dry mouth, decreased hidde, untimary frequency, anangaranis, rhinitis and ratis prevention. Adverse Events Occurring of an Incidence of 1%: Tolke 2 enumerates obvecee events that occurred at a frequency of 1% or more, and were more frequent than in the placebe group, among patients treated with LUVAS that is two shorterm placebo controlled OCD trials (10 week) and depression trials (6 week) in which patients were dosed in a range of generally 100 to 300 mg/day. term placebo controlled OD trids (10 week) and depression this (6 week) in which potents were dosed in a range of generally 10 by a 300 mg/d in his blab shows the perentange of potentia in each growth had at least one occurrence of an event at some time during their healment. Reported adverse events were classified using a standard COSIART-based Dictionary terminology. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where potent characteristics and other fectors may differ from those that prevaided in the clinical trids. Similarly, the crited requesties cannot be compared with fligures obtained from other clinical investigations involving distribution and investigations. The clinical trids. Similarly, the crited fligures, however, do provide the prescribing physicion with some basis for estimating the relative contribution of drug and mortaling tractics the side-effect inclinate rate in the population studied. Adverses Events in OCO Placebo Controlled Studies Which are Markedly Different (defined as at least a two-fold difference) in Rate from the Pooled Event Rates in OCD and Depression Markedly Different (defined as at least a two-fold difference) in Rate from the Pooled Event Rates in OCD and Depression
Placebo Controlled Studies: The events in OCD studies with a two-fold decrease in tate companed to event rates in OCD and depression studies were
dysphagia and anthyopia (mostly blurred vision). Additionally, there was an approximate 25% decrease in nausea. The events in OCD and depression studies were: astheria, abnormal ejaculation (mostly delayed ejaculation), anxiety,
infection, thinitis, anargasmia (in males), depression, fibido decreased, pharyrajitis, agriation, impotence, myoclonus/haith, thirst, weight loss, leg cramps,
myolgia and urinary relevation. These events are listed in order of decreasing rates in the OCD thick.
Virtal Sign Changes
Comparisons of fluoroxamine maleate and placebo groups in separate pools of short-term OCD and depression trials on (1) median change from baseline on
various vital signs variables and on (2) incidence of potients meeting criteria for potentially important changes from baseline on various vital signs variables
revealed no important differences between thivoxamine maleate and placebo.

revealed on important orienterects perviewen travoximate missers and process.

Congestions of flavoxomine molecte and placebo groups in separate pools of short-term OCD and depression trials on (1) median change from baseline on various serum chemistry, hematology, and urinalysis variables and on (2) incidence of potients meeting criteria for potentially important changes from baseline on various serum chemistry, hematology, and urinalysis variables revealed no important differences between fluvoxomine molecte and placebo.

Comparisons of theoromine molecte and placebo groups in separate pools of short-term OCO and depression trials on (1) mean change from baseline on various ECG variables and on (2) incidence of patients meeting criteria for patentially important changes from baseline on various ECG variables revealed no important differences between fluvoxamine maleate and placebo.

Compositors of throwcomine modelet and placebo groups in seporate pools of short-term UCD and depression indis and (1) mean change from boseline or various ECG variobles and on (2) incidence of placetine integrating criteria for placetine property important differences between flavouromine modelet and placebo.

Table 2: TREATRENT-EMERGENT ADVERSE EVYMIT INCIDENCE RATES BY SODY SYSTEM. IN OCD AND DEPRESSION POPULATIONS COMBINED! (flavouromine [ne-872] vs. placebo [ne-778] by potients—percentage): BODY AS WHOLE: Headcock (22 vs. 20); Asthesia (14 vs. 6); By Systems (23 vs. 2); Cital (2 vs. 1). ACRIDOVASCULAR Fepitations (23 vs. 2). DieESTIVES SYSTEM: Nature (40 vs. 2); Diestopica (10 vs. 5); Acridovascular (10 vs. 5); Acridovascular (10 vs. 5); Acridovascular (11 vs. 7); Caracipations (10 vs. 6); Diestopica (12 vs. 1); Diestopica (13 vs. 1)

Based on the number of females. Based on the number of males.

# Non-US Postmarketing Reports

Voluntury reports of otherse events in patients taking LUVOX Tablets that have been received since market introduction and are of unknown causal relationship to LUVOX Tablets use include: toxic epidermal necodysis, Stevens-Johnson syndrome, Henoch-Schoenlein purpura, bullous emption, priopism, organulocytoxis, neuropathy, oplostis conemia, anaphylactic reaction, hyponatemia, acute renal failure, hapatitis, and severe ckimesia with fever when fluvoramine was cardinalisteral with antipsychotic medication. CAUTION: Federal law prohibits dispensing without prescription

Reference: 1. Data on file, Solvay Pharmaceuticals, Inc.

Pharmacia & Upjohn

Solvay **Pharmaceuticals** 

# INTRODUCING A NEW INDICATION

# Break the debilitating cycle of childhood OCD

LUVOX® Tablets—the first SSRI indicated for obsessive compulsive disorder in children and adolescents



- Concomitant use of LUVOX® Tablets and monoamine oxidase inhibitors is not recommended.¹ Fluvoxamine should not be used in combination with terfenadine, astemizole or cisapride.
- Decreased appetite and weight loss have been observed with the use of fluvoxamine as well as with other SSRIs. Regular monitoring of weight and growth is recommended.

Please see brief summary of prescribing information on adjacent page.